DIRS.INFO The most relevant business & tech news

☆ Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Apple, Live Nation, Boeing, Coinbase, Amazon & more
▼ + stars: | 2024-04-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Bank of America reiterates Tesla as buy Bank of America said it's standing by its buy rating on the electric-vehicle maker. "We maintain our Buy rating and raise our PT from $1100 to $1,150." "We are initiating coverage of Live Nation with a Buy rating and $120 price target." "We are initiating coverage on EE with an Overweight rating." "We are initiating coverage of Integral Ad Science with a Buy rating and a $15 price target."

Persons: Tesla, TSLA, Morgan Stanley, Oppenheimer, Raymond James, Mizuho, Airbnb, Coinbase, Needham, Stephens, Jefferies, Ralph Lauren, Chegg Organizations: Argus, Boeing, " Bank of America, Bank of America, UBS, Nvidia, Dyne, JPMorgan, Catalyst Watch, Apple, Mizuho, Citi, BTC, Ethereum, Paramount, CBS, Deutsche Bank, Deutsche, Excelerate Energy, Stephens, Barclays, UMB, Corp, Contineum Locations: Base, Kansas City

☆ Inside the investing strategy of Hunterbrook Capital, the news-driven hedge fund. Can it succeed in a ruthless industry?
▼ + stars: | 2024-04-29 | by ( Bradley Saacks | ) www.businessinsider.com time to read: +6 min

Small team, limited scopeThe hedge fund makes trades based solely on news from Hunterbrook Media, its media sister company, sometimes getting advanced copies of the articles and placing trades before publication. AdvertisementThe hedge fund, however, has just one sole full-time employee. Before a story is published on Hunterbrook Media, the firm's general counsel reviews it to make sure there's not any insider information — such as leaked earning figures — in it. AdvertisementIf the general counsel and the executives green light the story to be shared, then it goes to the hedge fund — in other words, Dunlevie and Horwitz — prepublication. Opportunities few and far between so farInvestigations from Hunterbrook Media so far have less than a 50% hit rate on turning into trades for the hedge fund.

Persons: —, Nate Anderson's Hindenburg, Carl Icahn's, Nathaniel Horwitz, Matt Murray, Paul Steiger, Bethany McLean, That's, Courtney Dunlevie, Horwitz, Sam Koppelman, Brian Koppelman, Dunlevie, Horwitz — prepublication, isn't, It's Horwitz, Matt, Pulitzer, Tony Horwitz, Geraldine Brooks, Cash, Hunterbrook, Marc Lasry, David Fialkow, Matt Cherwin, we're, " Horwitz Organizations: Service, Business, Hunterbrook, Hunterbrook Media, Wall Street, Barclays, Commonstock, Phoenix Suns, Avenue Capital, Catalyst, JPMorgan Locations: Italian, Korean, Brazil

☆ ‘This is a unique time’: ARK Invest’s chief futurist tackles tech innovation from AI to robotics
▼ + stars: | 2024-04-27 | by ( Meredith Mutter | ) www.cnbc.com time to read: +1 min

ARK Invest's chief futurist lists five groups that should give tech investors an edge. "We believe that this is a unique time in technological economic history," he told CNBC's "ETF Edge" this week. Winton collaborates with ARK Invest CEO Cathie Wood to maintain the ARK Venture Fund (ARKVX), which allows investors to buy into the private technology space. "That's a real challenge a lot of public market investors don't have that long-term view," Winton added. The ARK Venture Fund is down more than 7% so far this year.

Persons: ARK, Brett Winton, CNBC's, Winton, Cathie Wood Organizations: ARK, ARK Venture, Epic, Therapeutics

☆ Stocks making the biggest moves after hours: Alphabet, Microsoft, Snap, Intel and more
▼ + stars: | 2024-04-25 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Microsoft – The tech giant saw shares climb 4.5% in extended trading after the software maker posted fiscal third-quarter results that surpassed Wall Street's expectations. Snap – Shares soared more than 27% in afterhours trading after the social media firm reported first-quarter results that beat analysts' estimates. Intel reported earnings that beat Wall Street expectations, however. Dexcom reported adjusted earnings of 32 cents per share on revenue of $921 million in revenue. Those results surpassed the earnings of $1.10 per share and $2.2 billion in revenue anticipated by analysts polled by LSEG.

Persons: Dexcom, FactSet, Gilead, Skechers, L3Harris, Macheel, Darla Mercado Organizations: Microsoft, Intel, Gilead Sciences, LSEG Locations: LSEG .

One strategist, however is looking keenly at European equities, and notes that "Europe isn't a boring market." "You would hope that will translate through to the stock market in terms of company earnings growth in Europe. "While you might see some kind of short-term downturn, in the longer-term the picture is very positive for the sector," Field added. He sees value in payments, which he described as "one of the most undervalued parts of European financial services." The sector has trailed market performance, with valuations looking "interesting" over the last 12 months, Morningstar noted in its recent report.

Persons: Michael Field, Field, Morningstar Organizations: CNBC Pro, European Central Bank, Consumer, Swatch Group, Financial, Morningstar, ING Bank, Group, Health, Novo Nordisk Locations: U.S, Europe, Netherlands, British, Swiss

☆ Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. Two-thirds of savings are associated with drug research and development, Bristol Myers Squibb executives said during an earnings call on Thursday. Those deals come as Bristol Myers faces pressure to launch new drugs and offset the potential loss of revenue from top-selling treatments. Shares of Bristol Myers fell more than 1% in premarket trading Tuesday.

Persons: Bristol Myers, Samit Hirawat, Chris Boerner, Boerner, Revlimid Organizations: Bristol Myers Squibb, Bristol Myers, Karuna Therapeutics, SystImmune, Bristol, LSEG Locations: Cambridge, Cambridge , Massachusetts, Here's

☆ Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
▼ + stars: | 2024-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Biogen on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected. Biogen and Eisai 's Leqembi became the first drug found to slow the progression of Alzheimer's disease to win approval in the U.S. in July. Leqembi brought in about $19 million in sales for the quarter, up from the $10 million the drug generated last year. In February, Biogen CEO Chris Viehbacher told reporters that there were around 2,000 patients currently on Leqembi. Adjusting for one-time items, the company reported earnings of $3.67 per share.

Persons: Biogen, Leqembi, FactSet, Chris Viehbacher, LSEG Organizations: LSEG Locations: U.S

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ Here are the portfolio's top 5 performing stocks since the March Monthly Meeting
▼ + stars: | 2024-04-24 | by ( Morgan Chittum | ) www.cnbc.com time to read: +7 min

Stocks hit a rough patch after the Club's March Monthly Meeting as Wall Street grappled with increasing odds of higher-for-longer interest rates. Here are our five top-performing stocks since the March Monthly Meeting. WFC YTD mountain Wells Fargo (WFC) year-to-date performance Wells Fargo led the way, with shares jumping 5.8% over the period. GOOGL YTD mountain Alphabet (GOOGL) year-to-date performance Alphabet stock rose 4.9% since the March Monthly Meeting, placing the Google parent in second place on the gainers list. EL YTD mountain Estee Lauder (EL) year-to-date performance Estee Lauder stock added 2.7% since the March Monthly Meeting, occupying the fourth spot on our list.

Persons: Stocks, Wells Fargo, Jim Cramer, Wells, Jim, he's, Lauder, Estee Lauder, Estee, Fabrizio Freda, Freda, Jim Cramer's, Dow, Spencer Platt Organizations: Dow Jones, Nasdaq, Club, Google, Big Tech, Palo Alto Networks, Bank of America, Citigroup, CNBC, Traders, New York Stock Exchange, Getty Locations: Wells, buybacks, Palo, Alto, New York City

☆ Grandmother Becomes Second Patient to Receive Kidney From Gene-Edited Pig
▼ + stars: | 2024-04-24 | by ( Roni Caryn Rabin | ) www.nytimes.com time to read: 1 min

A severely ill 54-year-old woman earlier this month became the second person to receive a kidney transplanted from a genetically modified pig, surgeons at NYU Langone Health in New York announced on Wednesday. The patient, who had both heart failure and kidney failure, was given the organ on April 12, just eight days after receiving a mechanical heart pump. Surgical teams at NYU Langone carried out the two procedures over the course of nine days. The kidney came from a genetically engineered pig provided by United Therapeutics Corporation, a biotech company. The pig carried a gene for producing a sugar called alpha-gal that had been “knocked out,” or blocked.

Persons: NYU Langone, Lisa Pisano, “ Organizations: NYU Langone Health, NYU, United Therapeutics Corporation Locations: New York, New Jersey

☆ Greenlight's David Einhorn builds new stake in this gambling name. Here's what else he bought
▼ + stars: | 2024-04-24 | by ( Adam Jeffery | ) www.cnbc.com time to read: +2 min

Greenlight Capital's David Einhorn continued to pick up new stocks in the first quarter, including Penn Entertainment , as the longtime value investor struggles to find opportunities in the volatile market. He established the stake at an average cost of $22.69 per share, but the stock has fallen to $17.44 as of Wednesday. Still, Einhorn said sports betting, if executed right, could take the shares much higher. "Were the market to credit PENN with merely 15% of DraftKings' value, that segment alone would be worth $20 per share." Q4 buyer's strike Einhorn had stopped building new stock positions at one point in the fourth quarter, saying he was on a "buyer's strike" due to worries about intensifying geopolitical risks.

Persons: Greenlight Capital's David Einhorn, Einhorn, PENN, he's, Greenlight, — CNBC's Leslie Picker Organizations: Penn Entertainment, CNBC, Barstool Sports, Cornell grad, Greenlight Capital, HP, Roivant Sciences, Liberty Global

☆ When Tesla shares rise — these 7 stocks have tended to rise too, according to recent history
▼ + stars: | 2024-04-24 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Seven stocks in the S & P 500 tend to rise alongside Tesla shares, according to an analysis of recent data by CNBC Pro . The share price performances of these S & P 500 stocks were highly correlated to Tesla's last month. However, unlike Tesla's more than 30% plunge this year, these stocks have either remained flat or have relatively modest negative returns. A correlation of zero would indicate no statistical link between the EV automaker's stock and the share price of the seven companies. The consensus upside potential for the stocks listed above was derived from FactSet's poll of analysts covering each stock.

Persons: Elon Musk, weathers, — CNBC's Lora Kolodny Organizations: CNBC Pro, Juniper Networks, Seagate Technology, Tyler Technologies, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, IDEXX Laboratories, EV, CNBC Locations: U.S, lockstep

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Broadcom : Broadcom's AI business, which includes co-designing custom chips for tech giants such as Club holding Alphabet, is booming. The newspaper reported April 12 that Salesforce was in talks to buy Informatica, which sent the Club holding's shares plunging. Wells Fargo : Another trim is due for our Wells Fargo position after a great run for the bank stock, Jim argued. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jim, Johnson, Abbott, Andy Jassy, Bausch, Salesforce, Salesforce didn't, Tom Jorden, We've, It's, Walt Disney, Nelson Peltz's, Bob Iger's, Estee Lauder, there's, Eaton, We're, he's, Locker, he'd, Vimal Kapur, Linde, Eli Lilly, Eli Lilly's, TikTok, Joe Biden, Morgan Stanley, Morgan Stanley's, Ted Pick, Jensen Huang, Nikesh Arora, haven't, Laxman Narasimhan, Sands, Stanley Black, Decker, TJ Maxx, TJX, Wells, Jim Cramer, Angela Weiss Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Johnson, Web Services, Broadcom, VMWare, GE Healthcare, GE, Bausch Health, Costco Wholesale, Costco, Street, Informatica, Coterra, DuPont De Nemours, DuPont, Walt, Disney, Ford, GM, Philips, Siemens, Google, Honeywell, Linde, Facebook, Meta, Microsoft, Nvidia, Investors, AMD, Oregon State University, Palo Alto Networks, UnitedHealth, Procter & Gamble, Constellation Brands, Constellation, Modelo, TJX, Marshalls, Home Goods, Wynn Resorts, Jim Cramer's Charitable, New York Stock Exchange, Afp, Getty Locations: China, Informatica, Ford, Estee, U.S, mater, Palo, Corona, Wells Fargo, Wells, Macao, New York City

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
▼ + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.

Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil

☆ A pullback in this biotech stock has created a buying opportunity, according to the charts
▼ + stars: | 2024-04-22 | by ( Katie Stockton | ) www.cnbc.com time to read: +2 min

Amgen has been in pullback mode since the beginning of February, losing roughly 13% within the context of its long-term uptrend. For those interested in "buying the dip," this may be a good time to revisit the stock, noting the decline looks overdone in the short term. There has been a positive reaction from AMGN to a short-term counter-trend "buy" signal from Tom DeMARK's TD Combo model, which supports a minimum two-week bounce. With Friday's reversal bar on AMGN's daily chart, combined with today's strength, our preferred momentum indicator the daily MACD is back on a "buy" signal. The MACD also shows a positive short-term divergence, supporting a bigger relief rally for AMGN in the near term.

Persons: Amgen, Tom DeMARK's Organizations: AMGN

☆ How Ozempic Is Transforming a Small Danish Town
▼ + stars: | 2024-04-20 | by ( Eshe Nelson | ) www.nytimes.com time to read: +1 min

As the sun sets over the harbor in Kalundborg, a small town about 60 miles west of Copenhagen, light streams through the glass walls of Shaun Gamble’s cafe and bathes his afternoon customers in a warm glow. Nearby, at a sprawling manufacturing plant, Novo Nordisk makes nearly all of its semaglutide, the active ingredient in the company’s wildly popular diabetes and obesity treatments Ozempic and Wegovy. It’s the largest manufacturing investment in Denmark by a company, and it’s happening in this town of fewer than 17,000 people. Novo Nordisk plans to add 1,250 jobs to the existing 4,500 employees at the Kalundborg plant. A highway is being extended; investors are snapping up houses and planning new construction; universities have begun offering biotech courses to feed Novo Nordisk and nearby businesses with workers.

Persons: Shaun Gamble’s Organizations: Novo Nordisk, Nordisk Locations: Kalundborg, Copenhagen, Denmark, Novo

☆ 6 portfolio stock earnings and the Fed's favorite inflation gauge dominate the week ahead
▼ + stars: | 2024-04-20 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

The Nasdaq sank 2% on Friday as Netflix dropped nearly 11% post-earnings and Club stock Nvidia fell 10%, entering bear market territory but still up more than 50% in 2024. Following a much stronger-than-expected March retail sales report last month, fresh economic data and six Club stock earnings will take center stage in the week ahead. While lower rates may help stock multiples, that is not a sustainable path to higher equity prices over time. Earnings : The latest quarterly reporting season is starting to ramp into high gear with six Club names set to report next week. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Dow, Jerome Powell, Jim Cramer, Mark, Meta, Bing, Ford, Vimal, Lockheed Martin, Clark, Philip Morris, Sherwin, Williams, Baker Hughes, Lam, Northrop, Dr Pepper, CARR, Edwards Lifesciences, Jim Cramer's, Jim, Michael M Organizations: Nasdaq, Netflix, Nvidia, Dow Jones, Federal, Fed, Hamas, Gross, Google, Reality Labs, General Motors, Honeywell, Microsoft, Verizon Communications, Albertsons Companies, SAP, Cadence Design Systems, United Parcel Service, General Electric, GE, PepsiCo, Lockheed, Spotify Technology, RTX Corporation, JetBlue Airways, Halliburton, HAL, Philip Morris International, Quest Diagnostics, Texas Instruments, Seagate Technology, Mattel, Veralto Corporation, Boeing, General Dynamics, Boston, Hilton, Fisher, Otis Worldwide, IBM, Grill, Viking Therapeutics, Lam Research, Whirlpool, WM, Honeywell International, Royal Caribbean Cruises, American Airlines, Altria, Newmont, Caterpillar, Southwest Airlines, Myers Squibb, AstraZeneca, Mobileye, Northrop Grumman, CNBC, Comcast, Merck, Dow Inc, Carrier Global, Union Pacific, Intel, Western, Mobile, L3Harris Technologies, Exxon Mobil, Chevron, Colgate, Palmolive, HCA Healthcare, Charter Communications, Newell Brands, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: Israel, Iran, Ukraine, destocking, China, Cleveland, Freeport, McMoRan, Kimberly, Masco, Bristol, New York City

☆ How R&D Funding Is Making the UK a Global Leader in Science
▼ + stars: | 2024-04-17 | by ( Sponsor Post | ) www.businessinsider.com time to read: +8 min

Exscientia's growth was bolstered by government support: The company didn't take venture funding until 2019. Exscientia wouldn't be where it was, Taylor said, without the support of the UK higher education system and government funding. Martin Tangney, the chief scientific officer of Edinburgh-based Celtic Renewables, said the £11 million of funding his company received in 2015 from the UK government was "pivotal." Advertisement"We really believe … [that] basically, soon all drugs are going to be created with AI," Taylor said. AdvertisementClick here to find out more about how your business can benefit from Research & Development in the UK.

Persons: Ben Taylor, Achilles, Taylor, —, We've, Smith, Nephew, we've, Martin Tangney, isn't, ABE, you've, Tangney Organizations: Nasdaq, University of Dundee, AstraZeneca, COVID, Celtic Renewables, biosciences, Department for Science, Innovation & Technology, Edinburgh Napier University, Government, Renewables, Research & Development, Insider Studios, UK's Department for Business & Trade, Innovation, Technology Locations: Oxford, UK, Edinburgh, Scotland, Ireland, Japan, America, India, Grangemouth

☆ Here are Wednesday's biggest analyst calls: Nvidia, Broadcom, Apple, Tesla, Netflix, Amazon, Microsoft & more
▼ + stars: | 2024-04-17 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Wednesday's biggest calls on Wall Street: Barclays reiterates Tesla as equal weight Barclays lowered its price target on Tesla to $180 per share from $225 and said it sees a negative catalyst heading into earnings. Wells Fargo reiterates Microsoft as overweight Wells raised its price target on the stock to $480 per share from $460. Barclays reiterates Broadcom as overweight Barclays raised its price target on Broadcom to $1,500 per share from $1,405. Wells Fargo reiterates Goldman Sachs as overweight Wells said it gives a "gold star" to Goldman coming out of earnings. Truist reiterates Amazon as buy Truist raised its price target on the stock to $216 per share from $195.

Persons: Tesla, Mizuho, RCL, Hancock Whitney, Raymond James, it's, Vernova, Wells, AAPL, TD Cowen, Jefferies, Morgan Stanley, NVDA, Goldman Sachs, Goldman, Maxim, Truist Organizations: Street, Barclays, Royal Caribbean, Citi, GE, HSBC, Biotech, Apple, Microsoft, Broadcom, Education, Strategic Education, Guggenheim, Automotive, Netflix Locations: China, Gulf

☆ This biotech stock specializing in targeted cancer treatments can surge 50%, Jefferies says
▼ + stars: | 2024-04-17 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Nuvalent could be a winning biotech in the world of cancer treatments, according to Jefferies. Analyst Roger Song initiated the clinical-stage biopharmaceutical company with a buy rating and $97 price target, which implies 49.8% potential upside for shares over the next 12 months. "NUVL leverages strong expertise in structure-based chemistry and deep understanding of unmet [patient] needs to develop potentially 'best-in-class' small molecule targeted cancer therapy," Song wrote in a Wednesday note. "We think both candidates poise well in later line and have strong potential to move into frontline treatments." The company posted a fourth-quarter loss that was slightly wider than expected, at 62 cents per share.

Persons: Roger Song, Jefferies Organizations: Jefferies, U.S . Food, Drug Administration, FactSet Locations: U.S

☆ The S&P 500's recent slump feels worse than it is. Here's some market perspective
▼ + stars: | 2024-04-17 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Sometimes the market just wants to come down even if the bonds are better," Jim Cramer said Wednesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, It's, we're, Abbott, We'll, Cramer, bode, Kinder, homebuilder D.R, Horton, Blackstone, Jim Cramer's, Jim Organizations: CNBC, United Airlines, UnitedHealth, Abbott Labs, Abbott Laboratories, Wall, Nvidia, Arm Holdings, Abercrombie, Fitch, Barclays, Broadcom, HSBC, Biotech, CSX, Alcoa, Alaska Air, Jim Cramer's Charitable Locations: what's

☆ Qureight uses AI to help speed up drug development. Check out the 11-slide pitch deck it used to raise $8.5 million.
▼ + stars: | 2024-04-16 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +2 min

British techbio startup Qureight has secured $8.5 million in an oversubscribed Series A round. Launched in 2018, Qureight wants to simplify how pharma companies deal with the complex datasets often used during clinical trials. "For example, we can start to structure images of lungs using AI," said cofounder and CEO Muhunthan Thillai. The startup primarily works with pharmaceutical companies, including heavyweights such as AstraZeneca, as well as hospitals and clinical research organizations. Check out the 11-slide pitch deck used to secure the fresh funding.

Persons: Qureight, Muhunthan Thillai, Thillai, Hargreave Hale Organizations: pharma, Business, AstraZeneca, Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Playfair, Fund, Cambridge Angels Locations: Cambridge, Meltwind

☆ Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs
▼ + stars: | 2024-04-15 | by ( Christina Jewett | ) www.nytimes.com time to read: +1 min

A Chinese company targeted by members of Congress over potential ties to the Chinese government makes blockbuster drugs for the American market that have been hailed as advances in the treatment of cancers, obesity and debilitating illnesses like cystic fibrosis. WuXi AppTec is one of several companies that lawmakers have identified as potential threats to the security of individual Americans’ genetic information and U.S. intellectual property. A Senate committee approved a bill in March that aides say is intended to push U.S. companies away from doing business with them. The Congressional spotlight on the company has rattled the pharmaceutical industry, which is already struggling with widespread drug shortages now at a 20-year high. Some biotech executives have pushed back, trying to impress on Congress that a sudden decoupling could take some drugs out of the pipeline for years.

Organizations: New York Times Locations: WuXi, U.S

☆ Biotech startup Seed Health is betting its profits on AI-powered medical science
▼ + stars: | 2024-04-11 | by ( Natalie Rose Goldberg | ) www.cnbc.com time to read: +7 min

On Thursday, Seed Health launched CODA, a computational biology platform funded by its consumer business profitability. Seed Health has been in the business of microbiome scientific breakthroughs since its founding in 2015, but its biggest success to-date may have been becoming profitable as a bioscience startup. Katz's co-founder and co-CEO at Seed Health, Raja Dhir, said CODA and the accompanying data set will help to standardize microbiome science methods, which has long been an issue in the field. CODA's first applications are in metabolic health, brain health, longevity, and menopause, research areas chosen because they have already been identified as areas of human health where early CODA data displayed the strongest evidence. Seed Health has been working on several efforts around pioneering microbiome science for human and planetary health, and many in the field believe the approach is destined to have wider applications.

Persons: Katz, Ara Katz, Eran Segal, Eric Topol, transcriptome, Katz's, Raja Dhir, Dhir, Arpana Gupta, Goodman, There's, Segal, Joseph Petrosino, Petrosino Organizations: Seed, Seed Health, CNBC, Weizmann Institute of Science, Scripps Research Institute, UCLA, Luskin Microbiome, Baylor College of Medicine, Center, Metagenomics, Microbiome Research

Search resuls for: "Biotech"

25 mentions found